Barasertib

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameBarasertib
Drug Alias NameBarasertibum巴雷舍替AZD-1152
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase Aurora-B inhibitors
TargetsSerine/threonine-protein kinase Aurora-B
Therapy Area/IndicationsSolid tumoursLymphomaLeukemia, Myeloid, Acute +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesRomaniaNetherlands +[10] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca PlcThe University Of Manchester
Active IndicationsN/A
Inactive IndicationsSolid tumoursLymphomaLeukemia, Myeloid, Acute +[5] 

Other Information

ATC CodeN/A
Related LinksN/A